Short answer
Altimmune, Inc. (ALT) filed an 8-K current report with the SEC on April 24, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $211.2M net proceeds raised through 64.25M shares and warrants for up to 10.75M shares.
Altimmune, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $211.2M net proceeds raised through 64.25M shares and warrants for up to 10.75M shares
- $3.00 exercise price creates substantial potential dilution alongside the equity issuance
- Funding targets pemvidutide’s global Phase 3 MASH trial and lead-program pre-commercial activities
- Warrants expire earlier of five years or 45 days after successful Phase 3 MASH data announcement
- Warrants will not be exchange-listed, limiting liquidity for warrant holders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Altimmune, Inc. 8-K filings
Get the next ALT 8-K as it lands
Follow ALT for push alerts, or ask the research agent what this filing means.